Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel
Frederic D Bushman1, Maire Conrad2, Yue Ren3
1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Insights
Children with inflammatory bowel disease (IBD) are susceptible to Clostridioides difficile infection (CDI). Metabolomic analysis revealed disease-specific gut microbiome patterns, identifying isocaproyltaurine as a potential biomarker for IBD and CDI.
Area of Science:
- Pediatric Gastroenterology
- Infectious Diseases
- Microbiome Research
Background:
- Children with inflammatory bowel diseases (IBD) face heightened risk of Clostridioides difficile infection (CDI).
- IBD and IBD + CDI share overlapping symptoms, necessitating distinct diagnostic biomarkers.
- Understanding the interplay between IBD, gut microbiome, and CDI is crucial for effective treatment.
Purpose of the Study:
- To investigate and compare the gut microbiome and metabolome in pediatric patients with IBD and IBD + CDI.
- To identify disease-specific metabolic patterns and potential biomarkers for differentiating these conditions.
- To explore the association between metabolic changes and susceptibility to CDI in pediatric IBD patients.
Main Methods:
- Longitudinal analysis of gut microbiome and metabolome data in pediatric patients.
- Comparison of IBD, IBD + CDI, and healthy control groups.
- Identification and characterization of key metabolites differentiating disease states.
Main Results:
- Gut microbiome exhibits dysbiosis and heterogeneity in both IBD and IBD + CDI.
- Metabolomic profiles reveal distinct patterns for IBD and IBD + CDI.
- IBD group shows elevated inflammation and tissue damage markers; metabolic changes correlate with CDI susceptibility.
- IBD + CDI samples contain metabolites linked to inflammation/tissue damage and C. difficile fermentation.
- Isocaproyltaurine identified as a highly discriminating metabolite, potentially marking both IBD and CDI.
Conclusions:
- Metabolomic analysis offers distinct patterns for pediatric IBD and IBD + CDI.
- Isocaproyltaurine shows promise as a joint biomarker for IBD and CDI in children.
- Further research can validate isocaproyltaurine for improved diagnostics and patient management.
Abstract:
Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infection with Clostridioides difficile (CDI). IBD and IBD + CDI have overlapping symptoms but respond to distinctive treatments, highlighting the need for diagnostic biomarkers. Here, we studied pediatric patients with IBD and IBD + CDI, comparing longitudinal data on the gut microbiome, metabolome, and other measures. The microbiome is dysbiotic and heterogeneous in both disease states, but the metabolome reveals disease-specific patterns. The IBD group shows increased concentrations of markers of inflammation and tissue damage compared with healthy controls, and metabolic changes associate with susceptibility to CDI. In IBD + CDI, we detect both metabolites associated with inflammation/tissue damage and fermentation products produced by C. difficile. The most discriminating metabolite found is isocaproyltaurine, a covalent conjugate of a distinctive C. difficile fermentation product (isocaproate) and an amino acid associated with tissue damage (taurine), which may be useful as a joint marker of the two disease processes.
More Related Videos
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...